Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kobe University, Kobe, Japan.
Carcinogenesis. 2021 May 28;42(5):672-684. doi: 10.1093/carcin/bgab014.
Hepatocellular carcinoma (HCC) developing after hepatitis C virus (HCV) eradication is a serious clinical concern. However, molecular basis for the hepatocarcinogenesis after sustained virologic response (SVR) remains unclear. In this study, we aimed to unveil the transcriptomic profile of post-SVR liver tissues and explore the molecules associated with post-SVR carcinogenesis. We analysed 90 RNA sequencing datasets, consisting of non-cancerous liver tissues including 20 post-SVR, 40 HCV-positive and 7 normal livers, along with Huh7 cell line specimens before and after HCV infection and eradication. Comparative analysis demonstrated that cell cycle- and mitochondrial function-associated pathways were altered only in HCV-positive non-cancerous liver tissues, whereas some cancer-related pathways were up-regulated in the non-cancerous liver tissues of both post-SVR and HCV-positive cases. The persistent up-regulation of carcinogenesis-associated gene clusters after viral clearance was reconfirmed through in vitro experiments, of which, CYR61, associated with liver fibrosis and carcinogenesis in several cancer types, was the top enriched gene and co-expressed with cell proliferation-associated gene modules. To evaluate whether this molecule could be a predictor of hepatocarcinogenesis after cure of HCV infection, we also examined 127 sera from independent HCV-positive cohorts treated with direct-acting antivirals (DAAs), including 60 post-SVR-HCC patients, and found that the elevated serum Cyr61 was significantly associated with early carcinogenesis after receiving DAA therapy. In conclusion, some oncogenic transcriptomic profiles are sustained in liver tissues after HCV eradication, which might be a molecular basis for the liver cancer development even after viral clearance. Among them, up-regulated CYR61 could be a possible biomarker for post-SVR-HCC.
丙型肝炎病毒 (HCV) 清除后发生的肝细胞癌 (HCC) 是一个严重的临床问题。然而,持续病毒学应答 (SVR) 后肝癌发生的分子基础仍不清楚。在这项研究中,我们旨在揭示 SVR 后肝组织的转录组特征,并探索与 SVR 后致癌相关的分子。我们分析了 90 个 RNA 测序数据集,包括非癌性肝组织,包括 20 个 SVR 后、40 个 HCV 阳性和 7 个正常肝组织,以及 Huh7 细胞系在 HCV 感染和清除前后的标本。比较分析表明,细胞周期和线粒体功能相关途径仅在 HCV 阳性非癌性肝组织中发生改变,而一些与癌症相关的途径在 SVR 后和 HCV 阳性病例的非癌性肝组织中上调。通过体外实验,再次证实了病毒清除后致癌相关基因簇的持续上调,其中与几种癌症类型的肝纤维化和致癌有关的 CYR61 是最富集的基因,并与细胞增殖相关基因模块共表达。为了评估该分子是否可以作为 HCV 感染治愈后肝癌发生的预测因子,我们还检查了来自接受直接作用抗病毒药物 (DAA) 治疗的 127 例独立 HCV 阳性队列的 127 份血清,包括 60 例 SVR-HCC 患者,发现血清 Cyr61 升高与接受 DAA 治疗后早期发生肝癌显著相关。总之,HCV 清除后肝组织中存在一些致癌转录组特征,这可能是病毒清除后肝癌发生的分子基础。其中,上调的 CYR61 可能是 SVR-HCC 的一个潜在生物标志物。